Brief: Synlogic And Ginkgo Bioworks Announce Investigational Synthetic Biotic Medicine For The Treatment Of Homocystinuria
09/11/2021 12:06
Nov 9 (Reuters) - Ginkgo Bioworks Holdings Inc DNA.N :
* SYNLOGIC AND GINKGO BIOWORKS ANNOUNCE INVESTIGATIONAL
SYNTHETIC
BIOTIC MEDICINE FOR THE TREATMENT OF HOMOCYSTINURIA
* SYNLOGIC- COLLABORATION GENERATES CLINICAL CANDIDATE
SYNB1353
USING SYNLOGIC'S PROPRIETARY SYNTHETIC BIOTIC PLATFORM AND
GINKGO CODEBASE
* SYNLOGIC - EXPECTS TO FILE IND APPLICATION WITH FDA FOR
SYNB1353
AND BEGIN CLINICAL DEVELOPMENT IN 2022
Source text for Eikon: ID:nPnmWbYda
Further company coverage: DNA.N
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Synlogic
See all newsBrief: Synlogic Receives Letter From Nasdaq Listing Qualifications Department On Nov 21 - SEC Filing
Brief: Synlogic Inc Files For Mixed Shelf Of Up To $150 Million – SEC Filing
Synlogic Inc reports results for the quarter ended September 30 - Earnings Summary
Synlogic Inc expected to post a loss of 10 cents a share - Earnings Preview
Synlogic Inc reports results for the quarter ended in January - Earnings Summary